

UUID: 315A77B4-1A2E-468D-9E44-FF0B07697943

TCGA-EW-A65C-01A-PR

Redacted



## Surgical Pathology Report

<b>Name:</b>	xxx	<b>Case #:</b>	x
<b>DOB:</b>		<b>Collected:</b>	
<b>Gender:</b>	F	<b>Received:</b>	x
<b>MRN:</b>	x	<b>Reported:</b>	x
<b>Location:</b>	xx		
<b>Physician:</b>	xxx		

### Pathologic Interpretation:

#### A. LEFT BREAST SENTINEL NODE 1

One lymph node, negative for carcinoma (0/1).

Immunohistochemistry for keratin is pending.

#### B. LEFT BREAST SENTINEL NODE 2

One lymph node, negative for carcinoma (0/1).

Immunohistochemistry for keratin is pending.

#### C. LEFT BREAST LUMPECTOMY:

INVASIVE LOBULAR CARCINOMA, moderately differentiated, Nottingham grade 2 (3+2+1=6), 2.1 cm in greatest dimension.

Immunohistochemistry performed on previous core needle biopsy demonstrated the following staining pattern in the lesional cells:

ER:	POSITIVE (> 50%)
PR:	POSITIVE (10-50%)
HER2:	NEGATIVE (0)
E-Cadherin:	NEGATIVE (0)

Resection margins are negative for carcinoma.

Prior biopsy site changes present.

Atypical ductal hyperplasia.

See Surgical Pathology Cancer Case Summary.

ICD-O-3  
 Carcinoma, lobular infiltrating  
 8520/3  
 Site: C&F  
 Breast HAS C50.9  
 path  
 Breast, upper-outer quadrant  
 C50.4  
 JWS 7/24/13

### **Surgical Pathology Cancer Case Summary**

#### Procedure

Excision without wire-guided localization

#### Lymph Node Sampling

Sentinel lymph node(s)

#### Specimen Laterality

Left

Tumor Site: Invasive Carcinoma

Position: 1 o'clock

Histologic Type of Invasive Carcinoma

Invasive lobular carcinoma

Tumor Size: Size of Largest Invasive Carcinoma

Greatest dimension of largest focus of invasion >1 mm: 21 mm

Histologic Grade: Nottingham Histologic Score

Glandular (Acinar)/Tubular Differentiation

Score 3: <10% of tumor area forming glandular/tubular structures

Nuclear Pleomorphism

Score 2: Cells larger than normal with open vesicular nuclei, visible nucleoli, and moderate variability in both size and shape

Mitotic Rate

Score 1 ( $\leq 3$  mitoses per  $\text{mm}^2$ )

Overall Grade

Grade 2: scores of 6 or 7

Tumor Focality (required only if more than 1 focus of invasive carcinoma is present)

Single focus of invasive carcinoma

Ductal Carcinoma In Situ (DCIS) (select all that apply)

No DCIS is present

Lobular Carcinoma In Situ (LCIS)

Not identified

Margins

Invasive Carcinoma

Margins uninvolved by invasive carcinoma

Distance from closest margin: 2.5 mm

Specify margin: Anterior

Lymph Nodes (required only if lymph nodes are present in the specimen)

Number of sentinel lymph nodes examined: 2

Total number of lymph nodes examined (sentinel and nonsentinel): 2

Number of lymph nodes with macrometastases (>2 mm): 0

Number of lymph nodes with micrometastases (>0.2 mm to 2 mm and/or >200 cells): 0

Method of Evaluation of Sentinel Lymph Nodes (select all that apply)

Hematoxylin and eosin (H&E), 1 level

H&E, multiple levels

Immunohistochemistry to follow

Treatment Effect: Response to Presurgical (Neoadjuvant) Therapy

In the Breast

No known presurgical therapy

In the Lymph Nodes

No known presurgical therapy

Lymph-Vascular Invasion

Not identified

Dermal Lymph-Vascular Invasion

No skin present

Pathologic Staging (based on information available to the pathologist) (pTNM)

Primary Tumor (Invasive Carcinoma) (pT)

pT2: Tumor >20 mm but  $\leq 50$  mm in greatest dimension

Regional Lymph Nodes (pN)

Modifier (required only if applicable)

(sn): Only sentinel node(s) evaluated

pN0: No regional lymph node metastasis identified histologically

Distant Metastasis (pM)

Not applicable

**Ancillary Studies**

(required only if available at time of report completion) (select all that apply)

Performed on another specimen

Specify specimen (accession number): —

Estrogen Receptor (ER)

Results and interpretation:

Positive Immunoreactive tumor cells present ( >50%)

Progesterone Receptor (PgR)

Results and interpretation:

Positive Immunoreactive tumor cells present (10-50%)

HER2

*Immunoperoxidase Studies*

Results:

Negative (Score 0)

Microcalcifications (select all that apply)

Present in invasive carcinoma

AJCC Classification (7<sup>th</sup> edition): pT2, (sn)pN0, pMn/a

Final AJCC classification will be issued after the keratin immunostain.

XX,  
XX,

\*\*\*Electronically Signed Out By\*\*\*

**Procedures/Addenda**

**Addendum**

**Date Ordered:**

**Status:**

**Date Complete:**

**Date Reported:**

**Addendum Diagnosis**

A. Immunohistochemistry for keratin is negative.

B. Immunohistochemistry for keratin is negative.

Final AJCC pT2 sn N0 (-) Mn/a

XX

**Intraoperative Consultation**

A. Sentinel node 1, FS: No malignancy seen. However, final diagnosis pending Immunohistochemical stains

B. Sentinel node 2, FS: No malignancy seen. However, final diagnosis pending Immunohistochemical stains

---

**Clinical History:**

Lobular carcinoma, ER+, RR+, HER (-)

**Operation Performed**

Left lumpectomy with sentinel node biopsy and possible axillary dissection

**Pre Operative Diagnosis:**

None Provided

**Specimen(s) Received/Processing Information:**

**Codes:**

